These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12366148)

  • 1. Properties of a "phase transition" induced by antiangiogenetic therapeutical protocols.
    Scalerandi M; Peggion F
    Phys Rev E Stat Nonlin Soft Matter Phys; 2002 Sep; 66(3 Pt 1):031903. PubMed ID: 12366148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion with evolving sources and competing sinks: development of angiogenesis.
    Scalerandi M; Sansone BC; Condat CA
    Phys Rev E Stat Nonlin Soft Matter Phys; 2002 Jan; 65(1 Pt 1):011902. PubMed ID: 11800713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coherent states of Gompertzian growth.
    Molski M; Konarski J
    Phys Rev E Stat Nonlin Soft Matter Phys; 2003 Aug; 68(2 Pt 1):021916. PubMed ID: 14525015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.
    Ogawa T; Takayama K; Takakura N; Kitano S; Ueno H
    Cancer Gene Ther; 2002 Aug; 9(8):633-40. PubMed ID: 12136423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
    Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
    Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
    Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of a "phase transition" from tumor growth to latency.
    Delsanto PP; Romano A; Scalerandi M; Pescarmona GP
    Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics; 2000 Aug; 62(2 Pt B):2547-54. PubMed ID: 11088735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies.
    Kohandel M; Kardar M; Milosevic M; Sivaloganathan S
    Phys Med Biol; 2007 Jul; 52(13):3665-77. PubMed ID: 17664569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis inhibitors in cancer therapy.
    Dredge K; Dalgleish AG; Marriott JB
    Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A two-dimensional model for studying tumor angiogenesis inhibitors.
    Gao P; Yang JL; Wang H; Wu XD; Jiao SC
    Cancer Invest; 2013 Jun; 31(5):346-58. PubMed ID: 23641911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy for cancer: current and emerging concepts.
    Jain RK
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
    Loges S; Mazzone M; Hohensinner P; Carmeliet P
    Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properties of the amniotic membrane may be applicable in cancer therapy.
    Seo JH; Kim YH; Kim JS
    Med Hypotheses; 2008; 70(4):812-4. PubMed ID: 17904762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.